Programmed cell death 1 ligand 1 — Drug Target

All drugs that target Programmed cell death 1 ligand 1 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Programmed Death Ligand-1 Blocker [EPC] · Programmed Death Receptor-1 Blocking Antibody [EPC]

Marketed (4)

• Imfinzi · AstraZeneca · Programmed Death Ligand-1 Blocker [EPC] · Oncology
  Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.
• Tecentriq · Roche · Programmed Death Receptor-1 Blocking Antibody [EPC] · Oncology
  Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system.
• Bavencio · Merck KGaA · Programmed Death Ligand-1 Blocker [EPC] · Oncology
  Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.
• Imfinzi · University Medical Center Groningen · Oncology